EZH2 and non-small cell lung carcinoma: It can inhibit cell growth and metastasis and facilitate chemotherapeutic sensitivity by targeting Pim‐1, TRIM44 or EZH2.22, 23, 24 Moreover, miR‐101‐3p suppresses the growth and metastasis of NSCLC by inactivation of PI3K/AKT signaling.25 Coinciding with this study, we found that miR‐101‐3p was downregulated in NSCLC tissues and its low expression was associated with poor survival in patients with NSCLC.